APX and Revelle Enter Strategic Partnership
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
Available in the EU, UK, and Switzerland, the device is designed for in-office preparation of autologous PRP and Fluid-PRF.
The expanded indication is based on clinical data showing high responder rates and results lasting up to 18 months, with no serious adverse events reported.